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Conch~,,~ions: Pie elected to PTCA have a granter likelihood of achieving 
early repodtmlen, However, In spite of that, percent mducllon of Infaml 
site ~nd the early recovery wore significantly lose tl~nn in pie undergoing 
thmmbolysls, Furthermore, we observed n trend towards lesser residual 
vl~bllty, The dol~y of treatment anent Is n critical factor which has to be 
carefully c0ostdomd bolero choosing dPTCA, A greater mpedusioo damage 
caused by abrupt mfl~w may also piny n role, 
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~ ~  Beneficial Effects of Enhanced External 
Countorpulutlon (EECP) tony Not Be Mediated 
by Changes In Myoeardlal Peffualon 
R,R, Afore, O, Aklnboboye, M Slitter, J,-W, tin, P,J, Cannon, S, Borgmann, 
Ceh.nbia Unh,emltV, C o l l e ~  of Phy.~ieian~ ~ Sturgeons, New York, N'K, USA 
EECP hns boon reported to decrease iscltemic symptoms in patients with 
nnglnn l'Oflectoly to maximal medical therapy who are not candidates for 
mvascularitalien Howovet, the mochaniem nl the beneficial effecta el EECP 
am tlncloar, To evahiato lhe offool el EECP on myocardial pedu~ion, my- 
ocardial blond flow Was measured using PET in 11 patients befog end alter 
35 sessions of dolly EECP All 11 patients had anginl'l refractory to medlc~J 
therapy nnd hod failed pnor bypa,~o surgery nn~ltor comna~ interventions 
Patients worn studied nt met and aflor dipyodomote, and myocardial perfu. 
eton was quontlfind with 13NH3 and a 2,compartment malhomattcnl model, 
Them were no chongos in either hemodyn0~mlcs nor in the area of ischomia 
as ~ result of EECP, Although them was a decrease in nitroglycerin use and 
enhanced exercise tolerance alter EECP, myocardial blood Ilow at rest or 
after dipyridamoto was not different in either ischemic or infamtod zones (I) 
or in non.ischomic amos (NIl (oven though these tomtorios worn supplied by 
diseased corollary artonos as documented by their limited myocardial flow 
reserve in response to dipyridamole) 
R,):~I Hyporomla 
l NI l NI 
Pro-EECP 73(19~ 96(17) 9S (46) 17~ (74) 
Post-EECP 74 ~,~oi BS (20) 105 (41) 165 (66) 
V~tuos ~lm mean I~e) in mr100 g/mln 
The results 3uqgest them is no change in the region at risk nor in absolute 
myocardial portusion either at rest or during hyperomia early alter EECP 
therapy. Salutory responses to EECP thernpy may therefore be independent 
el =Is effects on myocardial peffusion. 
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Myocardial revasculantation exerts favourable effects on prognosis and qual- 
ity ot life in patients (pts) with severe coronary artery disease (CAD). Aim 
of this study was to assess survival and quality of lile in pts with diffuse 
CAD, not eligible for revascularization From a retrospective analysis of 1100 
pts undergoing diagnostic cardiac catheterization for angina pectods, we 
selected 64 pts (5.8%-59 males, mean age 55.3 years, range 39-66) with 
diffuse CAD None of the pts underwent ~ny revascularization procedure, all 
were discharged on full medical therapy and to,owed-up for an average time 
of 101.3 months (range 36-184). For study purposes we correlated angina 
type. presence/absence of previous myocardial infarction (MI), ejection frac- 
tion (EF) and magnitude of left ventricular (LV) wall motion abnormalities 
(WMA) with event.hoe survival. At the end of monitoring, 60.2% of pts was 
alive, of whom 333% was asymptomatic, 31% had improved symptoms and 
35 7°0 without changes in symptoms severity. Survival was 46% and 84.2% 
in pts with/without previous MI (p = 0,004), EF .~ 50% was present in 78,6% 
of asymptomatle pts, 92.3% of those with reduced symptoms and 66.7% of 
those with unchanged symptoms, 21,4% end 45,5% of surviving/not surviv- 
ing pte had an EF .- 50% (p = 0,026), Survival was 76,P/c, in pts wlth normal 
LV function or localized hypoklnosia, 53,5% of those with diffuse hypokinosia 
nnd/or localized aklnesln, nnd 42,8% of pts with LV nnoun/sm, 
In r, oncluslon, LV function Is confirmed as the most Important progoostic 
factor In patients with aovore CAD, The high prevalence of pie with m. 
ducod/absent symptoms end the good survival rate might be due to currently 
improved therapeutic ntrntegtes nnd/or to an unintentional prevalence o! pts 
with good global LV function included in our study, 
• Results of Pereutaneoua Intervention for 
Unprotected Left Main Coronary StQnoaea In 
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Both stealing iS) ~lnd directional athem~fomy (DCA) have re~ent!y t~en pro. 
posed as mnsonab!e Ntematives to CABG for patients (pts) with unprotected 
loll main stenosos (ULMS) To ascertain m!t~mes for pta at different CABG 
ask we quened e, mglsmj at 22g consecutively treated non acute MI pts 
treated nt 25 centers since t ~4, Angles were cam lab reviewed with 75% 
!~lO fellow up, 13% of inoperable ple had cancer or other tile.limiting illness. 
USUal IR=sk High R isk  Inol~table 
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LVEF (%) 50 t 10 45, ~ 15= 41 ~ 18, 
Rosl;pmgr engm~ (%l 286 45 8 67 7 
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In,hosplhlt 
Cardiac d~th (%1 17 102 19 4 
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Em CABG t%) 0 e O O 0 O 
tlestenosts (",,) 23 3 269 50 O 
t0 month do,'tlh (%l ? 4 20 9 57 t 
12 monlh dentil, MI or GAnG i%t 19 O 33 t 59 4 
Clinical vanables strongly influence outcome el percutaneous tpere) rx ot 
ULMS, Pore rx may be reasonable m some settings, although the 5.7% el 
post-dischargo doeth at 12 rues. tot usual nsk pts is womsome. 
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Since patients (pts) with syndrome X (SX, angina, normal coronas/artenes. 
ischemia-liko ECG changes on exercise testing) have a good long term prog- 
nosis, the only aim of treatment is the reliel of symptoms. Yet, no previous 
study has directly compared th,3 effect e! standard anti-ischemic drugs on the 
frequency o! anginal episodes in these pts. Thus, we pedormed a double- 
blind, controlled, crossover thai on the effects of conventional anti-ischemtc 
therapy (beta-blockers, calcium-antagonists, nitrates) on anginal symptoms 
in 10 pts (57 ± 7 years, 4 men) with SX, who had - 3  anginal episodes per 
week. After a 4-week run-in period, pts were treated with either amlodipine 
(AML, 10 mg), isosorbide 5-mononitrate (ISMN, 40 rag), or atenolol (ATEN, 
100 mg), given once a day tm a penod of 4 weeks each, in a randomised 
cross-over order. Pts reported the occurrence of anginal episodes on an 
appropriately structured diary. Quality of life was assessed through a visual 
analogic scale (0 to 100 ram). A significant improvement or worsening was 
defined as a reduction or an increase of ~ 25°o of anginal episodes compared 
to run-in. The main results are summadzed in the table. 
Run-in ISMN AML ATEN 
Anginal episodes 23 -, 18 24 i 22 21 ,~ 22 15 ~ 13" 
Quality of lifq 22 ~ 16 30 :t 27 51 ± 25" 59 :~ 29" 
Pts improved 4 5 6 
Pts worsened 3 3 0 
• P • e OS VS run-in 
Thus, our data suggest that beta-blockers are, on average, more effective 
than ether classic antiischemic drugs in controlling anginal episodes in SX 
pls. 
